Introduction {#sec1-1759091418818261}
============

Glioblastoma multiforme (GBM) carries the highest mortality rate among primary brain tumors and remains largely unmanageable. Life expectancy following diagnosis is only about 12 to 14 months. This has changed little for decades despite continuing research (Fisher and Buffler, 2005; [@bibr109-1759091418818261]; [@bibr229-1759091418818261]; [@bibr113-1759091418818261]; [@bibr3-1759091418818261]; [@bibr7-1759091418818261]). Indeed, a recent reevaluation found that overall survival for GBM is woefully similar to that reported by Cushing almost a century ago ([@bibr63-1759091418818261]). A defining characteristic of GBM is the *secondary structures of Scherer*, which include diffuse parenchymal growth invasion over the subpial surface, along white matter tracks, and through the Virchow--Robin spaces ([@bibr195-1759091418818261]; [@bibr114-1759091418818261]; [@bibr104-1759091418818261]; [@bibr281-1759091418818261]; [@bibr216-1759091418818261]). The highly invasive nature of GBM makes most current therapies ineffective (Chang et al., 2005; [@bibr109-1759091418818261]; [@bibr43-1759091418818261]; [@bibr171-1759091418818261]). Although the introduction of the toxic alkylating agent, temozolomide, has improved progression-free survival slightly, quality of life has also remained poor for most GBM patients especially for those receiving radiation alone (Taphoorn et al., 2005; [@bibr230-1759091418818261]; [@bibr68-1759091418818261]).

GBM contains a plethora of morphologically diverse neoplastic cell types that express neural, glial, and myeloid/mesenchymal markers ([@bibr190-1759091418818261]; [@bibr145-1759091418818261]; [@bibr266-1759091418818261]; [@bibr186-1759091418818261]; [@bibr200-1759091418818261]; [@bibr278-1759091418818261]; [@bibr85-1759091418818261]; [@bibr93-1759091418818261]). Also recognized are abnormalities in the number, structure, and function of mitochondria in GBM cells ([Figure 1](#fig1-1759091418818261){ref-type="fig"}). Several groups have documented GBM cells with reduced or increased numbers of morphologically abnormal mitochondria with laminations and aberrant or absent cristae ([@bibr221-1759091418818261]; [@bibr194-1759091418818261]; [@bibr161-1759091418818261]; [@bibr12-1759091418818261]; [@bibr94-1759091418818261]; [@bibr51-1759091418818261]; [@bibr64-1759091418818261]; [@bibr212-1759091418818261]). Some mitochondria in human GBM cells contain few, if any, cristae ([@bibr12-1759091418818261]). In murine GBM, the content and composition of cardiolipin, the signature lipid of the mitochondrial inner membrane that regulates oxidative phosphorylation (OxPhos), exhibit considerable deviations from the normal ([@bibr96-1759091418818261]; [@bibr41-1759091418818261]). A multitude of findings support the notion that OxPhos is defective in GBM ([@bibr122-1759091418818261]; [@bibr64-1759091418818261]; [@bibr18-1759091418818261]; [@bibr44-1759091418818261]). Based on the concept that mitochondrial structure determines mitochondrial function ([@bibr117-1759091418818261]), these multiple mitochondrial abnormalities, which are of genetic or environmental origin, would be expected to compromise effective energy production through OxPhos ([@bibr211-1759091418818261]; [@bibr208-1759091418818261]).

![Morphological abnormalities in GBM mitochondria; (a) to (d) (distributed under a Creative Commons license) were reproduced from [@bibr51-1759091418818261]. The morphology of 150 mitochondria was assessed in six GBM samples and in seven peritumoural control samples using electron microscopy. (a) Percentage of normal mitochondria where cristae were visible throughout the mitochondria in peritumoural control and GBM samples (each bar represents one sample; \*\*\**p* value = .0001); (b) Percentage of abnormal mitochondria where cristae were sparse and abnormal in peritumoural control and GBM samples (\*\*\**p* value = .0001). (c and d) Representative electron microscopy images of normal and abnormal mitochondria, respectively. The scale bars represent 0.5 µm. Cristolysis was significantly greater in mitochondria from GBM than from control brain. The possibility cannot be excluded that the abnormal GBM mitochondria shown in panel (d) originate from areas close to necrotic palisades and might not be representative of mitochondria in all types GBM cells.\
GBM = glioblastoma multiforme.](10.1177_1759091418818261-fig1){#fig1-1759091418818261}

In view of the documented abnormalities in GBM mitochondria, alternative energy source(s) to OxPhos must be in place to maintain cell viability. Accumulating evidence indicates that glucose and glutamine are the primary fuels used for driving the rapid growth of most tumors, including GBM ([@bibr50-1759091418818261]; [@bibr272-1759091418818261]). Abundant levels of glucose and glutamine are also available in cyst fluid that is often present in GBM and could be used as fuel for the growing tumor cells ([@bibr44-1759091418818261]). Other potential metabolic fuels in the tumor microenvironment, for example, acetate and branched-chain amino acids, are either not present in sufficient quantities to drive growth through fermentation or exert nonmetabolic effects that are yet to be understood ([@bibr88-1759091418818261]; [@bibr212-1759091418818261]). While amino acids other than glutamine could also be fuels, they would require energy for preparation prior to their catabolism (see later). Glucose drives tumor growth through aerobic fermentation (Warburg effect), whereas glutamine drives tumor growth through glutaminolysis ([@bibr184-1759091418818261]; [@bibr49-1759091418818261]; [@bibr67-1759091418818261]; [@bibr273-1759091418818261]). Metabolism of glucose and glutamine is also responsible for the high antioxidant capacity of the tumor cells, thus making them resistant to chemo- and radiotherapies ([@bibr9-1759091418818261]; [@bibr269-1759091418818261]; [@bibr212-1759091418818261]). It remains unclear, however, whether glutamine is used primarily as a substrate for citric acid cycle anaplerosis and lipid synthesis or if it is also used as a major substrate for energy production through mitochondrial substrate-level phosphorylation (mSLP). This review describes a framework for how provision of high-energy phosphates through mSLP could compensate for the loss of energy production through both glycolysis and OxPhos in GBM. The information reviewed is derived from a broad range of experimental materials including human glioma tissue, validated preclinical models of GBM, and cultured glioma cell lines. Advantages and disadvantages associated with some of the models systems were presented previously ([@bibr203-1759091418818261]; [@bibr210-1759091418818261]).

Role of Glucose and Glycolysis in GBM Energy Metabolism {#sec2-1759091418818261}
=======================================================

Warburg originally proposed that cancer originated from an irreversible damage to cellular respiration that was followed by a gradual increase in fermentation, that is, glucose metabolized through glycolysis, leading to excessive formation of lactate ([@bibr258-1759091418818261]). The increased fermentation, which was present even in saturating partial pressures of oxygen, was necessary to compensate for a loss of energy through OxPhos. Aerobic fermentation is also a metabolic hallmark of GBM ([@bibr100-1759091418818261]; [@bibr184-1759091418818261]; [@bibr122-1759091418818261]; [@bibr161-1759091418818261]; [@bibr188-1759091418818261]). Despite the aforementioned evidence showing that mitochondria are abnormal in GBM tumor tissue, some investigators have claimed that mitochondria and OxPhos are normal in GBM and other brain tumor types based mostly, but not exclusively, on *in vitro* studies of oxygen consumption rates in tumor cells ([@bibr60-1759091418818261]; [@bibr263-1759091418818261]; [@bibr173-1759091418818261]; [@bibr287-1759091418818261]; [@bibr87-1759091418818261]; [@bibr127-1759091418818261]; [@bibr260-1759091418818261]; [@bibr271-1759091418818261]; [@bibr135-1759091418818261]). It is not clear how these findings can be reconciled in light of the abnormalities reported in the number, structure, and function of GBM mitochondria obtained from GBM tissue sections (referenced earlier). Discrepancies between *in vivo* and *in vitro* studies related to mitochondrial structure and function were not discussed in most of these studies. Warburg also proposed that oxygen consumption could be similar in tumor cells and normal cells but that ATP output from respiration would be less in the former than in the latter.

Despite the widely held view that oxygen consumption in cultured cells is a biomarker for OxPhos activity, many studies have since established that oxygen consumption is not linked to OxPhos ATP output in various tumor cell lines ([@bibr11-1759091418818261]; [@bibr181-1759091418818261]; [@bibr82-1759091418818261]; [@bibr119-1759091418818261]; [@bibr162-1759091418818261]). It is not possible, however, to exclude a complete absence of OxPhos in tumor cells, as [@bibr82-1759091418818261] showed that coupling was reduced by about 50% even in an *extreme case* of V600EBRAF-induced OxPhos dysfunction in melanoma cells. It is important to emphasize, however, that a ∼50% reduction in OxPhos would dissipate the protonmotive force and cause reversal of the F0-F1 ATP synthase ([@bibr33-1759091418818261]). The F0-F1 ATP synthase generally operates in forward mode (i.e., generating ATP) only when mitochondria are sufficiently polarized. It would not be possible for the F0-F1 ATP synthase to generate ATP under a loss of electron transport chain (ETC) operation on the order of 45% to 50% and would actually hydrolyze ATP, pumping protons out of the matrix. Reversal of the ATP synthase is what affords mSLP the critical role of providing ATP directly within the matrix when OxPhos becomes inhibited or impaired. These considerations are further addressed in the section below on, Role of Adenine Nucleotide Translocase and F0-F1 ATP synthase in GBM. Furthermore, the possibility of an inverse relationship between OxPhos efficiency and tumor aggression has been reported ([@bibr225-1759091418818261]). Warburg and Burk also described a similar phenomenon with respect to the degree of fermentation and tumor growth, that is, the more aggressive is the cancer, the greater is the fermentation ([@bibr258-1759091418818261]; [@bibr25-1759091418818261]). It is also documented that estimates of mitochondrial OxPhos efficiency can differ between *in vivo* and *in vitro* environments ([@bibr230-1759091418818261]; [@bibr97-1759091418818261]). Viewed collectively, these studies indicate that oxygen consumption alone cannot be used as a measure of normal respiration in cultured cells including GBM cells.

Another misconception comes from findings that aerobic glycolysis is required not only for GBM cell proliferation but also for proliferation of nontransformed cells grown *in vitro*, thus giving the impression that aerobic glycolysis is a normal phenomenon of cell proliferation ([@bibr249-1759091418818261]). This phenomenon does not, however, occur in proliferating nontransformed cells grown *in vivo*, for example, regenerating liver cells and normal colon cells, which use fatty acids and butyrate as fuel, respectively ([@bibr258-1759091418818261]; [@bibr220-1759091418818261]; [@bibr81-1759091418818261]; [@bibr242-1759091418818261]). We also showed that the *in vitro* growth environment suppresses Complex I activity and forces normal astrocytes to ferment through a Crabtree-linked effect ([@bibr97-1759091418818261]). This *in vitro* effect would obscure differences in energy metabolism between normal brain cells and GBM cells. Indeed, Warburg and Burk cautioned against generalizations made on cellular energy metabolism based *solely* on *in vitro* studies ([@bibr24-1759091418818261]; [@bibr258-1759091418818261]). It is glucose and not lactate that primarily drives brain energy metabolism ([@bibr8-1759091418818261]; [@bibr54-1759091418818261]; [@bibr154-1759091418818261]), making it unlikely that lactate could serve as a major energy metabolite for neoplastic GBM cells with diminished OxPhos capacity. A continued production of lactate in the presence of saturating partial pressures of oxygen is indicative of an impaired Pasteur effect, which itself could be linked to respiratory impairment ([@bibr180-1759091418818261]). Proliferation is the default state of metazoan cells and, together with fermentation, was the dominant phenotype of all cells in the *alpha* period before oxygen entered the atmosphere ([@bibr235-1759091418818261]; [@bibr226-1759091418818261]). Respiratory impairment or inhibition, arising from either genetic or environmental causes, could thus force cells into a fermentation metabolism with consequent proliferation ([@bibr211-1759091418818261]).

While it is well recognized that biochemical pathways are reprogramed in GBM and in other cancers ([@bibr249-1759091418818261]; [@bibr260-1759091418818261]), it remains unclear how GBM cells would generate sufficient energy with the documented abnormalities in their mitochondria. A reanalysis of how tumor cells obtain energy and metabolites for growth can help elucidate the origin of energy synthesis in GBM. The rate of glycolysis is increased in GBM, which is necessary for supporting growth under hypoxic conditions that commonly occur in the interior of the tumor mass ([@bibr188-1759091418818261]), shuttling glycolytic intermediates for building blocks of new cells. The upregulation of this pathway is due in part to hypoxia-induced stabilization of hypoxia-inducing factor 1α (HIF-1α), which amplifies the transcription of genes encoding glucose transporters and glycolytic enzymes ([@bibr198-1759091418818261]). Oncogenic signaling pathways, including phosphoinositide 3-kinase, can activate HIF-1α under normoxic conditions ([@bibr175-1759091418818261]). Mutations in tumor suppressor proteins such as the von Hippel--Lindau tumor suppressor gene product ([@bibr91-1759091418818261]), succinate dehydrogenase (SDH; [@bibr197-1759091418818261]), and fumarate hydratase (FH) can also activate HIF-1α ([@bibr99-1759091418818261]). Due to the cellular heterogeneity of GBM, it is likely that individual cells harbor one or more of these mutations ([@bibr224-1759091418818261]). It should also be recognized that the upregulation of oncogenes in GBM and most other cancers is necessary to facilitate substrate-level phosphorylation when OxPhos becomes unable to maintain the differentiated state ([@bibr208-1759091418818261]). Relevant to this, dysregulated tumor cell growth and oncogene expression are often abolished when the cancer nucleus is placed in a cytoplasm containing normal mitochondria or when normal mitochondria replace tumor mitochondria in the cytoplasm ([@bibr202-1759091418818261]; [@bibr92-1759091418818261]; [@bibr206-1759091418818261]). These findings indicate that normal mitochondrial functions can downregulate oncogenic signaling pathways restoring normal metabolic programing regardless of the genetic abnormalities present in the tumor cells. Indeed, recent findings of cancer driver mutations in normal cells seriously challenge the role of somatic mutations in the origin of cancer ([@bibr130-1759091418818261]) including in the brain ([@bibr153-1759091418818261] and references therein).

The enhanced use of glucose is thought to provide essential intermediates for tumor cell growth and proliferation by diverting metabolites into the pentose phosphate pathway ([@bibr86-1759091418818261]), as well as providing intermediates for lipid synthesis, the hexosamine pathway, and the synthesis of uridine diphosphate glucose ([@bibr249-1759091418818261]). More recently, it was shown that breast cancer cells could maintain rapid growth and proliferation by diverting 3-phosphoglycerate from glycolysis to generate serine and glycine through phosphoglycerate dehydrogenase (PHGDH; [@bibr177-1759091418818261]). Interestingly, suppression of PHGDH expression decreased cell proliferation but did not affect intracellular serine levels. On the other hand, reduced PHGDH expression was associated with reduced levels of α-ketoglutarate ([@bibr177-1759091418818261]), the main precursor for mSLP (see later). This mechanism also appears to operate in GBM ([@bibr124-1759091418818261]). It should also be recognized that blood glucose levels are directly correlated with GBM growth, that is, the higher the blood glucose, the faster the growth and less the survival, while the lower the blood glucose, the slower the growth and the greater the survival ([@bibr210-1759091418818261]; [@bibr141-1759091418818261]; [@bibr52-1759091418818261]; [@bibr136-1759091418818261]; [@bibr244-1759091418818261]).

In tumor cells, glycolytic intermediates escape *leak-down* toward pyruvate formation and subsequent entry into the mitochondria, being shunted toward the aforementioned subsidiary pathways by the preferential expression of the M2 isoform of pyruvate kinase (PKM2). Pyruvate kinase (PK) catalyzes the rate-limiting, ATP-generating *payoff* step of glycolysis in which phosphoenolpyruvate (PEP) is converted to pyruvate ([@bibr137-1759091418818261]). Multiple isoenzymes of PK exist in mammals. The type L is found in liver and kidneys, the type R in erythrocytes, type M1 in muscle and brain, and type M2 in embryonic and adult stem cells ([@bibr137-1759091418818261]). GBM cells appear to switch from the PKM1 to PKM2 isoform ([@bibr53-1759091418818261]). Unlike PKM1, which promotes glycolysis and rapid energy generation, PKM2 may attain a dimeric form that exhibits low affinity to its substrate PEP rendering it inactive at physiological PEP concentrations ([@bibr40-1759091418818261]). The high GBM cellular heterogeneity makes it difficult to deduce with certainty, which cells exhibit the dimeric versus tetrameric PKM2 form ([@bibr127-1759091418818261]; [@bibr53-1759091418818261]; [@bibr224-1759091418818261]). Preferential expression of PKM2 over PKM1 is mediated by modulating exon splicing, promoted by the oncoprotein Myc ([@bibr47-1759091418818261]). HIF-1α also induces transcription of PKM2, but not PKM1, and PKM2 serves as a cotranscriptional activator of HIF-1α, mediated by the proline hydroxylase PHD3 ([@bibr126-1759091418818261]). A major paradox regarding PKM2 is that cells expressing it produce more glucose-derived pyruvate than PKM1-expressing cells, despite the diminished activity of the M2 isoenzyme compared with M1. One way to achieve this is through a proposed alternative glycolytic pathway involving an enzymatic activity not yet purified that dephosphorylates PEP to pyruvate, without generating ATP ([@bibr250-1759091418818261]). Alternatively, the decreased enzymatic activity of PKM2 promoting accumulation of 3-phosphoglycerate may serve as an entry point for serine synthesis. In this pathway, serine dehydratase can directly convert serine to pyruvate ([@bibr260-1759091418818261]). Most recently though, PKM2 was reported to localize to the nucleus activating transcription of MEK5, a protein kinase that belongs to the *MAP kinase kinase* family involved in growth factor-stimulated cell proliferation, using PEP as a phosphate donor ([@bibr74-1759091418818261]). The latter study highlighted an important link between altered metabolism and gene expression in carcinogenesis and created a precedent for considering roles of metabolic intermediates other than those participating in classical biochemical pathways.

The fate of pyruvate in GBM is mostly conversion to lactate, by lactate dehydrogenase (LDH), rather than entry into mitochondria (see later). LDH is a tetramer composed of two different subunits, LDHA and LDHB, which can assemble into five different combinations ([@bibr128-1759091418818261]). Augmented expression of Myc-mediated LDHA is a hallmark of many tumors, the majority of which are highly glycolytic and are associated with a poor prognosis ([@bibr45-1759091418818261]; [@bibr107-1759091418818261]). LDHA is the predominant isoform in GBM and most other malignant cancers ([@bibr147-1759091418818261]; [@bibr120-1759091418818261]). The association of LDHB with cancer is more complex ([@bibr57-1759091418818261]) and is not likely to play a major role in GBM growth. LDHA catabolizes pyruvate to lactate producing NAD^+^, which is necessary to drive glycolysis by GAPDH ([@bibr48-1759091418818261]; [@bibr120-1759091418818261]). The reaction catalyzed by the cytosolic malate dehydrogenase (MDH1) was also recently shown to contribute to NAD^+^ provision ([@bibr75-1759091418818261]). Furthermore, lactate acidifies the tumor microenvironment ([@bibr62-1759091418818261]; [@bibr77-1759091418818261]), which enhances the activity of several proinvasive factors ([@bibr78-1759091418818261]; [@bibr167-1759091418818261]). Recent studies show, however, that it is carbonic anhydrase, and not LDH, that is mostly responsible for tumor-induced acidification ([@bibr233-1759091418818261]). Nonetheless, lactate efflux provokes a local inflammatory response attracting macrophages that secrete cytokines and growth factors promoting tumor cell growth and metastasis ([@bibr200-1759091418818261]; [@bibr61-1759091418818261]). The importance of LDHA activity in acidifying the microenvironment and creating a local inflammatory response, together with the provision of NAD^+^ for GAPDH regarding tumor survival, is reflected by the fact that LDHA inhibitors are becoming promising antitumor agents ([@bibr20-1759091418818261]; [@bibr57-1759091418818261]; [@bibr120-1759091418818261]). Relevant to this, downregulation of LDHA in gliomas with mutations in isocitrate dehydrogenase (IDH) appeared responsible for slow growth and better prognosis ([@bibr32-1759091418818261]). This was probably mediated by increased methylation of the LDHA promoter because silencing of LDHA in brain tumor stem cells exhibiting mutations in IDH was associated with slower growth ([@bibr32-1759091418818261]). [@bibr62-1759091418818261] and [@bibr120-1759091418818261] also found that silencing LDHA could reduce tumor progression. Furthermore, [@bibr284-1759091418818261] showed that additional epigenetic reprogramming, including immune-related genes, is likely to be involved in the pathogenesis of gliomas exhibiting mutations in IDH. IDH mutant glioma cells acquire resistance to natural killer (NK) cells through epigenetic silencing of NKG2D ligands.

Role of Pyruvate Dehydrogenase Complex and Pyruvate Carboxylase in GBM {#sec3-1759091418818261}
======================================================================

Pyruvate has three fates following entry into the mitochondria in normal cells, (a) conversion to oxaloacetate by pyruvate carboxylase (PC), (b) conversion to acetyl-CoA by the pyruvate dehydrogenase complex (PDHC), and (c) transamination with glutamate to α-ketoglutarate and alanine by a mitochondrial alanine aminotransferase. In GBM cells, however, both PDHC and PC are usually downregulated ([@bibr31-1759091418818261]; [@bibr279-1759091418818261]). HIF-1α, Myc, and other tyrosine kinases activate pyruvate dehydrogenase kinases (PDKs), which phosphorylate and thus inactivate the mitochondrial PDHC ([@bibr166-1759091418818261]). PC activity is suppressed in several cancer cell types ([@bibr28-1759091418818261]), including glioma cells ([@bibr176-1759091418818261]). Accordingly, PC is induced only when tumors grow in a glutamine-independent manner ([@bibr31-1759091418818261]). Inhibition of mitochondrial pyruvate catabolism is critical for tumor survival. Inhibition of PDK1 activates PDHC, with dichloroacetate, a drug used for the treatment of hereditary lactic acidosis. This then results in suppression of tumor growth *in vitro* and *in vivo* ([@bibr144-1759091418818261]). In GBM, due to the high cellular heterogeneity, pyruvate metabolism through PDHC and PC exhibits cell-dependent variability ([@bibr127-1759091418818261]). However, the consensus is that PDHC, an NAD^+^ and CoASH-requiring enzyme complex, and PC, an ATP-hydrolyzing enzyme, are downregulated in cancer mitochondria. We discuss in the following sections how downregulation of PDHC *free up* CoASH for α-ketoglutarate dehydrogenase complex (KGDHC), a critical reaction by which mSLP produces high-energy phosphates through glutaminolysis.

From the earlier considerations, it is evident that pyruvate metabolism by mitochondria is limited in GBM and that the high glycolytic rate may not generate adequate amounts of ATP due to a hindered payoff phase. This concept is depicted in [Figure 2](#fig2-1759091418818261){ref-type="fig"}. Accordingly, the high glycolytic rate seen in GBM is needed more for rapid synthesis of growth metabolites than for ATP synthesis. Relevant to this, no alternative cytosolic pathways are known that could generate sufficient ATP to replace energy loss through glycolysis and OxPhos.

![Energetics of glycolysis and OxPhos in normal tissue (a) versus GBM (b). In GBM, the diminished activity of dimeric PKM2 to generate ATP yields a net ≥0 ATP output from glycolysis. Also, because GBM mitochondria exhibit a dysfunctional ETC and a reverse-operating F0-F~1~ ATP synthase, they are ATP consumers (≤0 ATP output). OxPhos in GBM mitochondria may operate at a diminished rate, and this is depicted by the gray-dashed arrows traversing complexes I, III, and IV implying diminished ability for proton expulsion.\
FADH = reduced form of flavin adenine dinucleotide; GBM = glioblastoma multiforme; GPI = phospohexose isomerase; HK = hexokinase (any isoform); LDH = lactate dehydrogenase; PEP = phosphoenolpyruvate; PFK = phosphofructokinase; PGK = phosphoglycerate kinase; PK = pyruvate kinase; PKM2 = pyruvate kinase M2 isoform, dimeric; BPG = biphosphoglycerate; 3-PG = 3-phosphoglycerate.](10.1177_1759091418818261-fig2){#fig2-1759091418818261}

Role of Citrate Metabolism in GBM {#sec4-1759091418818261}
=================================

Acetyl-CoA is required for the cytosolic synthesis of fatty acids, cholesterol, and isoprenoid synthesis ([@bibr255-1759091418818261]). Acetyl-CoA cannot be directly exported to the cytoplasm but instead must first condense with oxaloacetate to form citrate through citrate synthase. Citrate is then converted to either isocitrate by aconitase (ACO2) or is exported to the cytosol where it is catabolized to acetyl-CoA and oxaloacetate by ATP-citrate lyase (ACL), at the expense of a high-energy phosphate bond provided by ATP. Acetyl-CoA is subsequently carboxylated to malonyl CoA also at the expense of a high-energy phosphate bond provided by ATP, initiating lipogenesis ([@bibr228-1759091418818261]). The importance of ACL is not only to catabolize citrate for the purpose of yielding acetyl-CoA, the building block for lipid synthesis in the cytoplasm, but also to decrease the concentration of citrate, which is a major negative allosteric modulator of phosphofructokinase, a rate-limiting step of glycolysis ([@bibr228-1759091418818261]). Akt facilitates the appearance of acetyl-CoA in the cytosol by phosphorylating and activating ACL ([@bibr19-1759091418818261]). Pharmacologic inhibition or silencing of ACL or acetyl-CoA carboxylase or fatty acid synthase decreases proliferation of cancer cells ([@bibr234-1759091418818261]), and especially GBM ([@bibr123-1759091418818261]; [@bibr116-1759091418818261]; [@bibr178-1759091418818261]). It is important to mention, however, that ACL is likely to have little importance in GBM, as GBM cells can acquire fatty acids from the microenvironment, thus bypassing an essential need for fatty acid synthesis ([@bibr236-1759091418818261]). However, many cancer cells exhibit a downregulation in the activity of PDHC, which results in diminished provision of acetyl-CoA in the mitochondrial matrix. In aggregate, it can be deduced that in GBM mitochondria, upregulations of ACL and acetyl-CoA carboxylase demand an adequate pool of cytosolic ATP.

Role of IDH in GBM {#sec5-1759091418818261}
==================

IDH exhibits three isoforms IDH1, NADP^+^-dependent isocitrate dehydrogenase (IDH2), and IDH3. IDH1 and IDH2 are homodimeric enzymes found in the cytoplasm and mitochondria, respectively, and produce NADPH. IDH1 and IDH2 are highly homologous but structurally and functionally distinct from the intramitochondrial IDH3, which produces NADH ([@bibr228-1759091418818261]). Many GBM cells exhibit reductive carboxylation of α-ketoglutarate to isocitrate by reversal of IDH and further isomerisation to citrate by ACO2, a pathway that was described in the early metabolic literature ([@bibr155-1759091418818261]) and has been investigated as a way to produce citrate for the purpose of lipogenesis from α-ketoglutarate derived from glutamine ([@bibr264-1759091418818261]). Furthermore, specific mutations in IDH1 and IDH2 are linked to tumorigenesis, in particular, GBM and acute myeloid leukemia ([@bibr270-1759091418818261]), but not other tumors ([@bibr21-1759091418818261]). It was shown that these mutations confer to IDH1 and IDH2 the ability to convert α-ketoglutarate to 2-hydroxyglutarate (2-HG) in a NADPH-dependent manner ([@bibr46-1759091418818261]; [@bibr156-1759091418818261]). Conversion of α-ketoglutarate to 2-HG could lower ATP production, as α-ketoglutarate would be needed as a substrate for mSLP (see later). As also discussed earlier, reduced α-ketoglutarate levels and LDHA silencing could explain in part the more favorable prognosis for those GBM patients harboring IDH mutations ([@bibr32-1759091418818261]).

Role of Glutamine Metabolism in GBM {#sec6-1759091418818261}
===================================

Substantial evidence exists documenting an important role for glutaminolysis and glutamine in cancer and specifically in GBM ([@bibr151-1759091418818261]; [@bibr142-1759091418818261]; [@bibr280-1759091418818261]; [@bibr49-1759091418818261]; [@bibr282-1759091418818261]; [@bibr125-1759091418818261]; [@bibr134-1759091418818261]; [@bibr157-1759091418818261]; [@bibr118-1759091418818261]). Since the 1950s, it was recognized that tumors require large amounts of glutamine for growth and survival (hence the inclusion of glutamine in most culture media). The high-affinity glutamine transporter Slc1a5 (ASCT2) is upregulated in multiple types of cancer including GBM and has been implicated in mediating net glutamine uptake ([@bibr219-1759091418818261]; [@bibr73-1759091418818261]). Even in the early studies, it was deduced that the high rate of glutamine consumption could not be fully accounted by protein synthesis because it exceeded the need for essential amino acids by an order of magnitude ([@bibr59-1759091418818261]). Several decades later, it was recognized that glutamine is a major energy source in tumor cells including GBM ([@bibr183-1759091418818261]; [@bibr189-1759091418818261]). The interconversion of glutamine and glutamate is bidirectional in normal cells, with glutamine synthetase catalyzing glutamine formation. In tumors, however, overexpression of glutaminases and suppression of glutamine synthetase favor the forward reaction toward glutamate ([@bibr170-1759091418818261]). Glutaminase activity correlates well with tumor growth rates in vivo ([@bibr106-1759091418818261]), especially for GBM ([@bibr215-1759091418818261]; [@bibr164-1759091418818261]). Glutaminase activity is critically important for GBM, as glutaminase and glutamate levels are elevated following treatment with mTOR kinase inhibitor ([@bibr170-1759091418818261]). Glutamine-derived glutamate also facilitates GBM invasion ([@bibr237-1759091418818261]). We also proposed that the most invasive cells of GBM are derived from neoplastic microglia/macrophages, which depend heavily on glutamine for growth ([@bibr85-1759091418818261]). Moreover, a decrease in glutaminase activity diminishes growth rates of many tumor cells including the metastatic VM-M3 GBM model ([@bibr215-1759091418818261]). Implantation of tumor tissue triggers a rapid increase in muscle glutamine output and a drop in muscle glutamine stores in rodents ([@bibr168-1759091418818261]). A similar burden has been suggested to occur in human tumors ([@bibr227-1759091418818261]). The consistency of high glutamine uptake in many tumors led to the development of glutamine PET tracers showing promise for the imaging of glutaminolysis ([@bibr256-1759091418818261]; [@bibr179-1759091418818261]). Although glutamine, like glucose, is a major energy metabolite for GBM, the mechanism by which glutamine generates energy remains unclear especially in tumor cells with abnormalities in the number, structure, and function of their mitochondria.

Some have suggested that GBM cells predominantly oxidize acetate rather than glutamine for growth ([@bibr127-1759091418818261]; [@bibr131-1759091418818261]). As both acetate and glutamine pass through the common KGDHC → succinate-CoA ligase (SUCL) → SDH pathway (see later), it remains to be resolved how acetate, but not glutamine, is catabolized to citric acid cycle intermediates. Relevant to this, acetate has been implicated as an epigenetic regulator of posttranslational protein modification and might actually have therapeutic potential in cancer management ([@bibr88-1759091418818261]). Thus, the role of acetate in GBM metabolism remains unclear.

The fate of glutamine in normal and tumor cells varies widely. An active synthesis of nitrogen-containing compounds, specifically nucleotides and nonessential amino acids (NEAAs), is required for tumor growth. Glutamine is the obligate nitrogen donor in at least three independent steps for purine synthesis including phosphoribosylpyrophosphate amidotranferase, phosphoribosylformylglycinamidine synthetase, and GMP synthetase. Glutamine is also important in two independent enzymatic steps for pyrimidine synthesis, carbamoyl phosphate synthetase II and CTP synthetase ([@bibr2-1759091418818261]; [@bibr277-1759091418818261]). Glutamine-derived glutamate is the primary nitrogen donor for the synthesis of NEAAs including asparagine ([@bibr2-1759091418818261]). This is interesting because asparagine is considered a growth metabolite for GBM and other tumors ([@bibr165-1759091418818261]; [@bibr105-1759091418818261]). The glutamine:fructose-6-phosphate amidotransferase reaction transfers the amide nitrogen of glutamine to form glucosamine-6-phosphate, a precursor for N-linked and O-linked glycosylation needed for hexosamine synthesis ([@bibr49-1759091418818261]). Although some have considered that glutamine can be metabolized to lactate through the malic enzyme to produce NADPH for lipid biosynthesis ([@bibr179-1759091418818261]), other findings indicate that little glutamine is metabolized to lactate in GBM and in other tumor cells ([@bibr236-1759091418818261]).

In addition to the previous reactions, glutamine also participates in the synthesis of glutathione (GSH) through GSH cysteine ligase, thus playing a major role in the maintenance of cellular redox homeostasis ([@bibr9-1759091418818261]; [@bibr115-1759091418818261]). GSH comprises glutamate, cysteine, and glycine. Glutamate contributes to the uptake of cystine ([@bibr193-1759091418818261]). Cystine can then be converted to cysteine inside the cell and used in GSH synthesis ([@bibr228-1759091418818261]). In addition, glutamine induces synthesis of manganese superoxide dismutase ([@bibr4-1759091418818261]), another powerful antioxidant system in mitochondria of GBM ([@bibr185-1759091418818261]; [@bibr218-1759091418818261]). Hence, glucose and glutamine metabolism can protect GBM from oxidative stress, thus making GBM resistant to radio- and chemotherapy ([@bibr212-1759091418818261]).

It is our view that glutamine not only provides nitrogen for synthesis of nucleotides and NEAAs but also provides α-ketoglutarate to serve as a precursor for ATP synthesis through substrate-level phosphorylation in the citric acid cycle. Relevant to this, it has been recently demonstrated that in fibroblasts from a patient with SUCL deficiency, glutamine oxidation was impaired (Chinopoulos et al., 2018). The availability of α-ketoglutarate may occur either through the glutamate dehydrogenase (GLUD1) reaction or through the transamination reaction ([@bibr49-1759091418818261]). Indeed, cells from GBM and other cancers rely on either GLUD1-mediated glutamate deamination ([@bibr193-1759091418818261]) or transamination ([@bibr261-1759091418818261]), thus providing α-ketoglutarate to the cycle. In at least one study, glutamate derived by transamination was suggested to be the major route ([@bibr146-1759091418818261]). Furthermore, selective inhibition of glutamate transamination with aminooxyacetic acid hindered tumor growth in the absence of nonspecific toxicity of complete inhibition of glutamine metabolism involving GLUD1 ([@bibr263-1759091418818261]). Oncogenic signals originating from Myc and perhaps also Ras induce all of the previously mentioned pathways involved in glutamine entry and ensuing glutaminolysis in tumor cells ([@bibr50-1759091418818261]; [@bibr261-1759091418818261]). Overall, it can be concluded that the mitochondria in GBM cells strongly depend on glutamine as a source of α-ketoglutarate that can be used for energy production through mSLP.

Role of the KGDHC in GBM {#sec7-1759091418818261}
========================

The KGDHC consists of multiple copies of three subunits: α-ketoglutarate dehydrogenase, dihydrolipoyl succinyltransferase, and dihydrolipoyl dehydrogenase. It catalyzes the conversion of α-ketoglutarate, CoASH, and NAD^+^ to succinyl-CoA, NADH, and CO~2~ and exhibits a high flux control coefficient in the generation of reducing equivalents and succinyl CoA ([@bibr217-1759091418818261]; [@bibr102-1759091418818261]). The PDHC and the KGDHC compete for the same pool of CoASH and NAD^+^ ([@bibr101-1759091418818261]). Even a small decrease in KGDHC activity will lead to a considerable decrease in substrate-level phosphorylation in the mitochondrial matrix ([@bibr38-1759091418818261]; [@bibr102-1759091418818261]). Hence, the diversion of α-ketoglutarate to 2-hydroxyglutarate could explain in part the improved overall survival of GBM patients containing the IDH mutations, as this diversion would reduce ATP synthesis through mSLP, thus reducing tumor growth.

Apart from tumor metabolism under ischemia or hypoxia, there is mounting evidence of pronounced conversion of α-ketoglutarate to succinate ([@bibr83-1759091418818261]), implying that KGDHC remains operational ([@bibr35-1759091418818261]). However, during anoxia, when the ability of Complex I to oxidize NADH to NAD^+^ is impaired, the question arises as to the origin of NAD^+^ for the KGDHC reaction. Under these conditions, we recently reported that mitochondrial diaphorases oxidize matrix NADH supplying NAD^+^ to KGDHC ([@bibr103-1759091418818261]; [@bibr182-1759091418818261]). Furthermore, we showed that Complex III of the respiratory chain mediated reoxidation of the reducible substrates for the diaphorases using endogenous quinones ([@bibr103-1759091418818261]). Regarding KGDHC and cancer, it can be deduced that in hypoxia/anoxia, when the rate of NADH oxidation by Complex I is reduced, mitochondrial diaphorases use endogenous quinones to regenerate NAD^+^ for the KGDHC reaction. This raises the possibility that downstream provision of succinyl CoA by KGDHC maintains substrate-level phosphorylation yielding ATP or GTP in the mitochondrial matrix. We now propose that mSLP provides the majority of energy needed to drive GBM growth. This concept was originally suggested for the VM-M3 murine glioblastoma cells (Seyfried, 2012d).

Role of SUCL {#sec8-1759091418818261}
============

SUCL is a heterodimeric enzyme, composed of an invariant α subunit encoded by SUCLG1 and a substrate-specific β subunit, encoded by either SUCLA2 or SUCLG2. This dimer combination results in either an ATP-forming (EC 6.2.1.5) or a GTP-forming SUCL (EC 6.2.1.4). The enzyme catalyzes the conversion of succinyl-CoA and ADP (or GDP) to CoASH, succinate, and ATP (or GTP). The ΔG' for this reaction is 0.07 kJ/mol, and it is reversible ([@bibr121-1759091418818261]). When SUCL proceeds in the direction toward succinyl-CoA, this product may follow heme- or ketone body metabolism ([@bibr160-1759091418818261]). On the other hand, the reaction proceeding toward ATP or GTP formation is termed *substrate-level phosphorylation* and can occur in the presence or absence of oxygen. Substrate-level phosphorylation during anoxia/ischemia rescues cells from cytosolic/nuclear ATP depletion. Moreover, this mechanism prevents mitochondria from reverting to ATP consumption by shifting the reversal potential (the mitochondrial membrane potential---ΔΨm---value at which there is no net transfer of ADP-ATP across the inner mitochondrial membrane) of the adenine nucleotide translocase (ANT) toward more negative values than the ΔΨm ([@bibr35-1759091418818261]; [@bibr102-1759091418818261]). Relevant to this, matrix inorganic phosphate activates SUCL and thus contributes to the anaerobic provision of ATP synthesis in mitochondria ([@bibr172-1759091418818261]). GTP is a central regulator of cellular anabolism ([@bibr163-1759091418818261]) and is used in mitochondria by the protein synthesis machinery, the PEP carboxykinase isoform 2, the GTP-AMP phosphotransferase, and by other GTP-binding proteins ([@bibr243-1759091418818261]). GTP-forming SUCL may support ATP formation in the matrix through the concerted action with a mitochondrial isoform of a nucleotide diphosphate kinase known as nm23-H4. This kinase complexes with either an ATP- or GTP-forming SUCL ([@bibr90-1759091418818261]; [@bibr108-1759091418818261]) and plays a role in the maintenance of mtDNA ([@bibr232-1759091418818261]). Interestingly, nm23-H4 was recently reported to exhibit a *moonlighting* function involving intermembrane lipid transfer operated by cardiolipin ([@bibr196-1759091418818261]). This property affords to the enzyme a regulatory role in lipid signaling of apoptosis. SUCL is not a critical enzyme in all tissues; for example, astrocytes in the human brain do not express SUCLA2 or SUCLG2 ([@bibr55-1759091418818261]); accordingly, these cells are expected not to exhibit SUCL activity. Finally, our recent studies show that ATP production through mSLP can support viability and growth in the VM-M3 glioblastoma cells ([@bibr69-1759091418818261]).

Role of SDH {#sec9-1759091418818261}
===========

SDH, also known as Respiratory Complex II, is an integral mitochondrial inner membrane protein complex that oxidizes succinate to fumarate and transfers two electrons to coenzyme Q. SDH is composed of four subunits: SDHA, SDHB, SDHC, and SDHD. The assembly of SDH requires two factors, SDH Assembly Factor 1 (SDHAF1) and SDHAF2 ([@bibr16-1759091418818261]). Mutations in some of its subunits or its assembly factors were shown to cause paragangliomas and pheochromocytomas ([@bibr16-1759091418818261]). In these tumors, the resulting inhibition of SDH increases mitochondrial and cytosolic succinate levels, inhibiting α‑ketoglutarate-dependent prolyl hydroxylases (PHDs), thus causing stabilization of HIF-1α ([@bibr111-1759091418818261]). HIF-1α mediates much of the genetic alterations of enzyme and transporter expressions mentioned earlier. In this sense, succinate has been considered a proinflammatory *oncometabolite* ([@bibr197-1759091418818261]; [@bibr238-1759091418818261]; [@bibr246-1759091418818261]). Succinate and fumarate also inhibit other α‑ketoglutarate-dependent dioxygenases, including the Jumonji‑C histone demethylases and the TET family of 5‑methylcytosine hydroxylases, resulting in genome-wide alterations of histone and DNA methylation and epigenetic dysregulation ([@bibr268-1759091418818261]). In other words, extranuclear mitochondrial abnormalities would underlie these nuclear epigenetic changes.

Although SDH mutations have not been reported in GBM, an increase in mRNA coding for SDH subunits has been shown in human GBM cells ([@bibr98-1759091418818261]). This is most relevant regarding mSLP because the accumulation of succinate, as it may occur by high flux through SUCL, will on one hand mediate HIF-1α stabilization and inhibition of Jumonji‑C histone demethylases and TET 5‑methylcytosine hydroxylases aggravating epigenetic dysregulation, but on the other hand, it may push the reversible SUCL reaction toward ATP (or GTP) consumption. It is also interesting that the interaction of SIRT5 (a lysine desuccinylase) with cardiolipin can influence SDH activity and the efficiency of the ETC ([@bibr285-1759091418818261]). The cardiolipin abnormalities we found in murine GBM might therefore influence SIRT5 function leading to enhancement of glutaminolysis and mSLP ([@bibr96-1759091418818261]; [@bibr257-1759091418818261]).

Role of FH {#sec10-1759091418818261}
==========

FH converts fumarate to malate in a reversible manner. Homozygous null mutations in the FH gene are associated with multiple cutaneous and uterine leiomyomatas and aggressive forms of renal cell cancer ([@bibr5-1759091418818261]). Although fumarate has also been hypothesized to inhibit PHDs, stabilization of HIF-1α was not required for tumorigenesis in FH^--/--^ mice ([@bibr1-1759091418818261]). Fumarate is an electrophilic unsaturated dicarboxylic acid, and as such it has the ability to bind reactive thiol residues of proteins in a process termed protein succination ([@bibr6-1759091418818261]). *Succination* must not to be confused with *succinylation*, the latter being a posttranslational modification of lysine residues using succinyl-CoA ([@bibr262-1759091418818261]). Several targets of fumarate have now been identified, and they include the negative regulator of NRF2, Keap1 ([@bibr158-1759091418818261]), ACO2 ([@bibr241-1759091418818261]), and GSH ([@bibr231-1759091418818261]). As such, fumarate has also achieved the status of an *oncometabolite* ([@bibr274-1759091418818261]). As of October 2018, FH and its role in GBM have not yet been addressed. However, it is anticipated that accumulation of fumarate, as it may occur by high flux through SUCL performing substrate-level phosphorylation followed by the action SDH, will mediate excessive succinations, potentially contributing to tumor progression through increased glutaminolysis ([@bibr257-1759091418818261]).

Role of Adenine Nucleotide Translocase and F0-F1 ATP Synthase in GBM {#sec11-1759091418818261}
====================================================================

Both the ANT and the F0-F1 ATP synthase can catalyze reversible processes. The ΔΨm and the *reversal potential* (Erev) determine the directionality of these processes, the latter determined by the concentrations of the participating reactants ([@bibr33-1759091418818261]). Extramitochondrial adenine nucleotides can contribute to matrix adenine nucleotide pool only through the ANT and, by a minor fraction, through the ATP-Mg/Pi carrier ([@bibr10-1759091418818261]). As it has been extensively addressed in our laboratory, substrate-level phosphorylation substantiated by succinyl CoA ligase generating ATP assists respiration-impaired mitochondria exhibiting diminished values of ΔΨm to retain high matrix ATP levels, sparing cells from cytosolic/nuclear ATP consumption ([@bibr33-1759091418818261]). This concept is inherently related to tumor metabolism generally and to GBM metabolism specifically, as the likelihood is high that GBM mitochondria exhibit diminished values of ΔΨm due to cristolysis and respiratory inhibition. Pinpointing the component(s) of the respiratory chain exhibiting defects leading to a decrease in respiratory capacity is a daunting task. This task is further complicated by the fact that the exact site of the defect in the respiratory chain will dictate whether a cell can be rescued by provision of substrates supporting mSLP ([@bibr36-1759091418818261]). In any case, respiratory arrest and ensuing decrease in ΔΨm would result in consumption of matrix ATP by the reverse-operating F0-F1 ATP synthase. The generation of matrix ATP by succinyl CoA ligase is instrumental in rescuing cancer cells from cytosolic ATP consumption. On the same line of thought, the ATPase Inhibitory Factor 1 exhibits stark changes in expression among various types of human carcinomas ([@bibr192-1759091418818261]) and has been linked to energy metabolism reprogramming, signaling the oncogenic phenotypes of cancer ([@bibr70-1759091418818261]). The critical information that can be obtained from this consideration is that substrate-level phosphorylation substantiated by succinyl CoA ligase generating ATP in the matrix assists respiration-impaired mitochondria that exhibit diminished values of ΔΨm in avoiding cytosolic ATP consumption, thus sparing cells from cytosolic/nuclear ATP depletion. This concept is inherently related to tumor metabolism because cancer mitochondria frequently exhibit diminished values of ΔΨm, a concept associated with the reverse operation of the F0-F1 ATP synthase and the consumption of matrix ATP.

From the above considerations, we have come to several insights regarding GBM metabolism from the earlier information: (a) The net balance of cytosolic ATP production is low despite having a high rate of glycolysis due to diminished production by the payoff phase substantiated by the reaction catalyzed by PKM2. (b) ATP is needed in the cytosol not only for maintenance of membrane ion pumps but also for ATP-consuming reactions of fatty acid synthesis. (c) The mitochondrial F0-F1 ATP synthase becomes an ATP consumer in pumping protons out of the matrix due to defects in the ETC. Consequently, little ATP is generated from either glycolysis or OxPhos, which increases the danger of mitochondria becoming net ATP consumers. (d) The branch of the citric acid cycle toward citrate formation becomes diminished due to lack of intramitochondrial catabolism of pyruvate. On the other hand, the rate of glutamine catabolism toward the citric acid cycle becomes high. (e) The obligate metabolites formed by this pathway are α-ketoglutarate, succinyl-CoA, and succinate. (f) This metabolite trio implies significant ATP (or GTP) synthesis through SUCL-mediated substrate-level phosphorylation. Maintenance of a high matrix ATP/ADP ratio also assures that the ANT provides ATP to the cytosol while also preventing the F0-F1 ATP synthase from draining cytosolic ATP reserves. The concomitant formation of succinate is efficiently shuttled outside the mitochondria but can also be metabolized to fumarate and malate, the latter supporting exchange of other metabolites across the inner mitochondrial membrane. An important question is whether other metabolites that converge on succinyl-CoA can also support ATP production in the mitochondrial matrix. This is addressed in the following section and in [Figure 3](#fig3-1759091418818261){ref-type="fig"}. We also recognize that our views might be considered as a conjecture until additional evidence is obtained to support our position.

![Pathways leading to ATP (or GTP) generation at the substrate level. Dashed arrows imply multiple enzymatic steps (omitted for clarity). Reduction of NAD^+^ to NADH by PDH is omitted for uncluttering the figure.\
α-Kg = α-ketoglutarate; ACSS1 = acetyl-coenzyme A synthetase 2-like, mitochondrial; BCKDH = branched-chain α-ketoacid dehydrogenase; GLSc = glutaminase, cytosolic; GLSm = glutaminase, mitochondrial; GLUD = glutamate dehydrogenase; GOT2 = aspartate aminotransferase; KGDHC = α-ketoglutarate dehydrogenase complex; MTHFD1L = monofunctional C1-tetrahydrofolate synthase; NME = nucleoside diphosphate kinase; OC-FA = odd-chain fatty acid; P*~i~* = inorganic phosphate; PP*~i~* = pyrophosphate; PC = pyruvate carboxylase; PDH = pyruvate dehydrogenase; PEP = phosphoenolpyruvate; PEPCKm = mitochondrial phosphoenolpyruvate carboxykinase; PK = pyruvate kinase; SAM = S-adenosylmethionine; SDH = succinate dehydrogenase; SDS = serine dehydratase; SUCL = succinate-CoA ligase; THF = tetrahydrofolate.](10.1177_1759091418818261-fig3){#fig3-1759091418818261}

Convergence of Metabolites Toward Succinyl-CoA and mSLP {#sec12-1759091418818261}
=======================================================

There are a number of metabolites that catabolize toward the citric acid cycle through succinyl-CoA, thus leading to ATP (or GTP) formation through SUCL. Our review of the relevant biochemistry, however, shows that only glutamine catabolism can yield a net ATP (or GTP) production though mSLP. As shown in [Figure 3](#fig3-1759091418818261){ref-type="fig"}, several metabolites eventually converge toward succinyl-CoA including the amino acids valine, isoleucine, methionine, histidine, threonine, glutamine, glutamate, and also propionate ([@bibr245-1759091418818261]; [@bibr112-1759091418818261]; [@bibr265-1759091418818261]; [@bibr223-1759091418818261]) and thymine ([@bibr228-1759091418818261]), and odd-chain fatty acids (OC-FAs). Except for glutamate and glutamine, however, the catabolism of all other metabolites *expends* one or more high-energy phosphates during metabolic interconversions before becoming succinyl-CoA. Support for mSLP can also come from conversion to glutamate (such as proline and arginine) or from other metabolites that catabolize toward α-ketoglutarate (such as glycine, serine, sarcosine, dimethylglycine through pyruvate, and fatty acids or leucine through acetyl-CoA). However, the concentrations of these metabolites in the plasma or in the microenvironment are far lower than that of glutamine and are therefore unlikely to make a major contribution to mSLP ([@bibr273-1759091418818261]). Dashed arrows in [Figure 3](#fig3-1759091418818261){ref-type="fig"} imply multiple enzymatic steps (omitted for the sake of clarity).

In addition to the pathways converging toward succinyl-CoA, there are two more ways for producing high-energy phosphates at the substrate level: first through the mitochondrial phosphoenolpyruvate carboxykinase, interconverting PEP and GDP to oxaloacetate and GTP (GTP, GDP, ADP, and ADP can interconvert through nucleoside diphosphate kinase isoforms) and second through the monofunctional C1-tetrahydrofolate (THF) synthase interconverting ADP, phosphate, and 10-formyltetrahydrofolate to ATP, formate, and THF. However, the mitochondrial phosphoenolpyruvate carboxykinase reaction is strongly favored toward PEP formation (thus consuming GTP) in a process called pyruvate recycling pathway ([@bibr72-1759091418818261]; [@bibr187-1759091418818261]; [@bibr42-1759091418818261]; [@bibr27-1759091418818261]; [@bibr110-1759091418818261]; [@bibr14-1759091418818261]; [@bibr80-1759091418818261]; [@bibr35-1759091418818261]). For this pathway, PEP enters mitochondria through a phosphate/PEP antiporter ([@bibr140-1759091418818261]), a protein with isoforms in members C, D, and E of the solute carrier family 35 ([@bibr252-1759091418818261]; [@bibr76-1759091418818261]; [@bibr159-1759091418818261]; [@bibr222-1759091418818261]). Finally, carboxylation of pyruvate by PC yielding oxaloacetate is a thermodynamically reversible reaction; however, backflow toward pyruvate leading to ATP production may occur only at a very low rate ([@bibr72-1759091418818261]; [@bibr138-1759091418818261]; [@bibr17-1759091418818261]). Consumption of one ATP in the reaction catalyzed by PC is also the reason why metabolites that converge to pyruvate (glycine, serine, sarcosine, and dimethylglycine) do not yield net ATP (or GTP) from mSLP. To date, the contribution of monofunctional C1-THF synthase on yielding ATP through substrate-level phosphorylation has not been adequately addressed. According to our analysis, glutamine would be the prime driver of mSLP and ATP production through SUCL. Evidence for our hypothesis was recently obtained from studies of the murine VM-M3 glioblastoma cells grown under hypoxia ([@bibr69-1759091418818261]).

Interactions Between Oxidative Decarboxylation, Provision of Reducing Equivalents, Reductive Carboxylation, and mSLP {#sec13-1759091418818261}
====================================================================================================================

From the earlier considerations, it is evident that only catabolism of glutamine or glutamate may lead to net ATP (or GTP) production through mSLP; this is entirely consistent with the extremely high glutamine dependence of many tumors including GBM. However, this prompts considering the following two concepts: (a) reductive carboxylation of glutamine toward citrate that exits mitochondria and is destined for fatty acid synthesis has been well-documented to occur in cancers ([@bibr75-1759091418818261]), and especially in GBM ([@bibr50-1759091418818261]; [@bibr236-1759091418818261]) and (b) oxidative decarboxylation of glutamine/glutamate toward mSLP substantiated by SUCL demands stable provision of NAD^+^ for KGDHC. Reductive carboxylation versus oxidative decarboxylation of glutamine/glutamate will *branch out* at the level of α-ketoglutarate, depicted in [Figure 4](#fig4-1759091418818261){ref-type="fig"}; in the former case, it will become isocitrate by the NADP^+^-dependent IDH2 and then citrate through reversal of ACO2; in the latter case, α-ketoglutarate will become succinyl-CoA by KGDHC and thus follow mSLP. Although both pathways start from α-ketoglutarate, they are not mutually exclusive; flux of glutamine/glutamate toward α-ketoglutarate is sufficiently high to support both pathways ([@bibr174-1759091418818261]; [@bibr273-1759091418818261]). Interestingly, it was recently shown that in cancer cell lines, the degree of OxPhos defects conferred by mtDNA mutations dictates whether α-ketoglutarate follows oxidative decarboxylation or reductive carboxylation ([@bibr30-1759091418818261]; [@bibr36-1759091418818261]). On the other hand, regarding oxidative decarboxylation in the absence of OxPhos during which the ability of Complex I in providing NAD^+^ is impaired, it has been shown that intramitochondrial diaphorases can contribute to the matrix NAD^+^ pool ([@bibr103-1759091418818261]). This reaction was, however, demonstrated only in isolated mitochondria in artificial conditions. It is currently not known how mitochondria *in situ* regenerate NAD^+^ in the absence of OxPhos; it is not even known if a residual, minimal remaining function of Complex I during hypoxia/anoxia is sufficient for providing NAD^+^ for KGDHC for supporting mSLP, in view of the fact that overall respiration has ceased. Apart from mitochondrial diaphorases, there are other pathways that can adopt this role; as shown in [Figure 4](#fig4-1759091418818261){ref-type="fig"}, the malate-aspartate shuttle can operate in reverse ([@bibr23-1759091418818261]; [@bibr39-1759091418818261]) and lead to a decrease in the matrix NADH/NAD^+^ ratio. For example, conditions that can lead to excessive NADH oxidation in the cytosol may lead to increased formation of oxaloacetate in the same compartment that will in turn lead to transamination with glutamate to aspartate and α-ketoglutarate; this will cause the exchange of cytosolic α-ketoglutarate with mitochondrial malate, shifting the equilibrium of MDH2 toward NADH oxidation, thus yielding NAD^+^ in the matrix. Furthermore, salvage reactions that can lead to NAD^+^ formation could also play a role ([@bibr276-1759091418818261]). Moreover, there are other potential intramitochondrial reactions that can lead to a decrease in matrix NADH/NAD^+^ ratio, such as those participating in THF metabolism ([@bibr275-1759091418818261]). The group of Vamsi Mootha has published a compendium of 342 reactions utilizing NAD(P)H, termed the NAD(P)ome ([@bibr79-1759091418818261]). Hence, there are likely several mechanisms by which cancer cells can obtain NAD^+^ in low-oxygen, hyper-reducing conditions.

![Provision of NAD^+^ in the matrix of mitochondria in the absence of OxPhos. Enzyme annotations as in Figures 2 and 3.\
α-Kg = α-ketoglutarate; ACO2 = aconitase; ACLY = ATP citrate lyase; FA = fatty acid; FAD = flavin adenine dinucleotide; GLSc = glutaminase, cytosolic; GLSm = glutaminase, mitochondrial; GLUD = glutamate dehydrogenase; GOT2 = aspartate aminotransferase; IDH2 = NADP^+^-dependent isocitrate dehydrogenase; KGDHC = α-ketoglutarate dehydrogenase complex; MDH = malate dehydrogenase; NME = nucleoside diphosphate kinase; SDH = succinate dehydrogenase; SUCL = succinate-CoA ligase.](10.1177_1759091418818261-fig4){#fig4-1759091418818261}

The Warburg Theory Revisited {#sec14-1759091418818261}
============================

It is our view that SUCL can provision ATP (or GTP), thus *bailing-in* cancer mitochondria from a reverse-operating F0-F1 ATP synthase when ETC function(s) are impaired but can also assist glycolysis in providing high-energy phosphates for energy-consuming processes. This mechanism has been previously suggested and is pertinent to GBM and other solid tumors with hypoxic centers ([@bibr211-1759091418818261]; [@bibr204-1759091418818261]; [@bibr212-1759091418818261]). Relevant to this, computer modeling of cancer metabolism predicted that a repression of SUCL would cause a significant reduction in growth rate, relative to known chemotherapeutic targets ([@bibr95-1759091418818261]). It has also not escaped our attention that mSLP could represent the *missing link* in Warburg's central theory that OxPhos insufficiency with compensatory fermentation is the origin of cancer. In addition to cytoplasmic substrate-level phosphorylation, that is, aerobic fermentation or the Warburg effect, mSLP could also compensate for insufficient or defective OxPhos, as we have described in this review. Unfortunately, the role of glutamine and mSLP was unknown to Warburg. Although most investigators have focused on aerobic fermentation (Warburg effect), we find it astonishing that almost all of the major reviews or previous studies on cancer energy metabolism have not addressed or even recognized the role of SUCL activity and mSLP, as a compensatory energy mechanism for deficient OxPhos. Based on our views, mSLP could become a key mechanism for energy production in tumor cells with defective respiration or for growth in hypoxic environments.

Confusion over the linkage of OxPhos to oxygen consumption and a general failure to recognize the role of mSLP as a compensatory energy mechanism have led many investigators to think that the ETC is normal in GBM and in other tumors. Further confusion could come in part from observations that GBM and other tumors might also use fatty acids and ketone bodies for growth ([@bibr22-1759091418818261]; [@bibr13-1759091418818261]; [@bibr169-1759091418818261]; [@bibr267-1759091418818261]; [@bibr89-1759091418818261]). Fats and ketone bodies, however, are nonfermentable fuels and would require oxidative respiration for energy generation. Recent studies show, however, that fats can upregulate glycolysis and glutaminolysis through uncoupling mechanisms ([@bibr191-1759091418818261]; [@bibr248-1759091418818261]; [@bibr254-1759091418818261]). Enhanced glucose and glutamine metabolism could therefore be an indirect effect of high-fat diets that are consumed in unrestricted amounts ([@bibr286-1759091418818261]). The numerous abnormalities in the number, structure, and function of GBM mitochondria mentioned earlier would be expected to alter the function of the ETC according to the predictions of [@bibr117-1759091418818261] and Ferreria (2010). Little ATP produced from glycolysis might also be expected for those tumors (GBM) where the dimeric PKM2 expression predominates over PKM1 expression. In light of the PKM2 issue, the convergence of metabolites toward succinyl-CoA and mSLP could provision sufficient ATP to maintain growth of GBM and possibly other tumors in hypoxic environments. As glutamine would be the major metabolite for provisioning ATP synthesis through mSLP under normoxic or hypoxic conditions in tumor cells, the phenomenon could be considered a *Warburg Q-Effect* to distinguish this effect from that involving the aerobic fermentation of glucose. Both effects arise from compromised OxPhos. Emerging evidence indicates that the mitochondrial metabolic theory can explain better the hallmarks of cancer than can the somatic mutation theory ([@bibr211-1759091418818261]; [@bibr204-1759091418818261]; [@bibr210-1759091418818261]; [@bibr206-1759091418818261]). Recognition of mSLP as a second major compensatory energy mechanism for tumor cells with defective or insufficient OxPhos could have profound implications for managing most tumors including GBM.

Considerations for Controlling GBM Cell Growth {#sec15-1759091418818261}
==============================================

It is widely recognized that glucose and glutamine are the major energy metabolites that drive GBM growth and invasion. Glucose and glutamine become the major fermentable fuels for heterogeneous GBM cells due to the inability of OxPhos to meet energy demands and for growth in hypoxic environments. Recent findings indicate that glutamine is the major fuel for GBM cells with mesenchymal molecular subtype, whereas glucose in the major fuel for GBM cells with proliferative subtype ([@bibr157-1759091418818261]). According to our concepts based on the underlying biochemistry discussed earlier, control of GBM cell growth could involve the simultaneous targeting of substrate-level phosphorylation reactions in the cytoplasm (glycolysis) and in the mitochondria (glutaminolysis). Although we do not make any recommendations for treatment of GBM in patients, a parsimonious consideration would be to restrict availability of glucose and glutamine to the tumor cells to downregulate both glycolysis and glutaminolysis simultaneously. This approach was shown to kill GBM and HeLa cells *in vitro* ([@bibr213-1759091418818261]; [@bibr132-1759091418818261]), as would be predicted from *ensemble* modeling of cancer metabolism ([@bibr95-1759091418818261]). No cell can grow without energy regardless of its genetic composition. Because ketone bodies can replace glucose as an energy source, prior studies show that glucose levels could be significantly reduced without harmful effects after first transitioning the body to therapeutic ketosis ([@bibr58-1759091418818261]; [@bibr207-1759091418818261]; [@bibr212-1759091418818261]). This fact was mentioned in the work of [@bibr26-1759091418818261] and was demonstrated in nine persons who received insulin injection after fasting for 2 months ([@bibr58-1759091418818261]). Indeed, the blood glucose level in one person in the insulin group reached as low as 9 mg/dl (0.5 mmol/l) without evidence of a hypoglycemic response ([@bibr58-1759091418818261]). These findings suggest that the glucose needed for GBM cell growth could be majorly restricted under therapeutic ketosis.

Ketone bodies also possess anti-inflammatory potential through reduction of reactive oxygen species and increase of GSH peroxidase activity in normal brain cells ([@bibr251-1759091418818261]; [@bibr209-1759091418818261]). Some studies have shown that GBM and other malignant brain tumors may have a reduced ability to utilize ketone bodies due in part to diminished activity of succinyl-CoA:3-ketoacid coenzyme A transferase 1, which is essential for metabolism of ketone bodies ([@bibr71-1759091418818261]; [@bibr286-1759091418818261]; [@bibr133-1759091418818261]). Glucose restriction under therapeutic ketosis or calorie restriction will downregulate the entire glycolytic pathway from glucose to pyruvate ([@bibr129-1759091418818261]). Glycolytic downregulation will not only deprive tumor cells of growth metabolites but will also reduce LDHA activity and lactate production, thus reducing angiogenesis and inflammation in the tumor microenvironment ([@bibr149-1759091418818261]; [@bibr129-1759091418818261]; [@bibr150-1759091418818261]; [@bibr247-1759091418818261]; [@bibr84-1759091418818261]; [@bibr253-1759091418818261]). Glucose restriction should also reduce the metabolites needed for serine-derived one-carbon metabolism, which would further reduce tumor cell antioxidant capacity and growth ([@bibr143-1759091418818261]; [@bibr199-1759091418818261]; [@bibr283-1759091418818261]). We also found that calorie restriction and restricted ketogenic diets, which lower blood glucose and elevate blood ketone bodies are proapoptotic against murine glioblastoma and neural stem cell tumors ([@bibr149-1759091418818261]; [@bibr214-1759091418818261]). Glucose targeting would also reduce metabolites generated through the pentose phosphate pathway that would be needed for the synthesis of GSH and growth metabolites.

From the biochemical point of view, catabolism of ketone bodies obligatorily bypasses mSLP. As shown in [Figure 5](#fig5-1759091418818261){ref-type="fig"}, the ketone bodies acetoacetate and β-hydroxybutyrate enter mitochondria and eventually the citric acid cycle as succinate, bypassing mSLP. This is because formation of succinate is not through SUCL but through succinyl-CoA:3-ketoacid coenzyme A transferase 1. By doing so, catabolism of both acetoacetate and β-hydroxybutyrate does not lead to the formation of high-energy phosphates through mSLP. Furthermore, β-hydroxybutyrate is expected to decrease mSLP through glutamine/glutamate even further because it increases NADH/NAD^+^ ratio, thus hindering KGDHC operation ([@bibr102-1759091418818261]). It is also essential to target glucose and glutamine together, as glutamine can be synthesized from glucose-derived glutamate through the glutamine synthetase activity ([@bibr240-1759091418818261]). Hence, the simultaneous restriction of glucose and glutamine, while under therapeutic ketosis, could halt growth of GBM cells that are more dependent on substrate-level phosphorylation than on OxPhos for survival.

![Ketone bodies bypass mSLP. Enzyme annotations as for Figures 2, 3, and 4.\
BDH = β-hydroxybutyrate dehydrogenase; FAD = flavin adenine dinucleotide; GLSc = glutaminase, cytosolic; GLSm = glutaminase, mitochondrial; GLUD = glutamate dehydrogenase; GOT2 = aspartate aminotransferase; KGDHC = α-ketoglutarate dehydrogenase complex; NME = nucleoside diphosphate kinase; OXCT1 = succinyl-CoA:3-ketoacid coenzyme A transferase 1; PC = pyruvate carboxylase; PDH = pyruvate dehydrogenase; PEP = phosphoenolpyruvate; PK = pyruvate kinase; SUCL = succinate-CoA ligase.](10.1177_1759091418818261-fig5){#fig5-1759091418818261}

It is important to mention that the targeting of glutamine is more challenging than is the targeting of glucose for GBM growth control. Glutamine, like glucose, is an essential metabolite for the neoplastic cells of GBM. Unlike glucose, however, glutamine is also an essential metabolite for cells of the gut, the immune system, and for general physiological homeostasis ([@bibr227-1759091418818261]; [@bibr152-1759091418818261]; [@bibr277-1759091418818261]). Consequently, glutamine targeting must be done carefully so as not to harm normal cell function or disrupt physiological homeostasis.

We recently proposed a *press-pulse* therapeutic strategy for managing most cancers including GBM while minimizing toxicity to normal cells and tissues ([@bibr212-1759091418818261]). The press-pulse concept was developed from the field of paleobiology in showing that the extinction of organisms during prior evolutionary epochs occurred in the ecosystem only when a chronic *press* disturbance coincided with an acute *pulse* disturbance. In our adaption of this concept for the cancer problem, press therapies are designed to reduce systemic glucose availability while elevating blood levels of ketone bodies, which tumor cells cannot effectively use for energy generation. This approach is designed to pit the metabolic demands of normal cells against those of the mutated tumor cells, which are less capable than normal cells in adapting to metabolic stress from nutrient deprivation due to accumulation of tumor mutations ([@bibr209-1759091418818261]; [@bibr212-1759091418818261]). Ketone body supplements could further reduce glucose levels while enhancing the respiratory energy metabolism in normal cells. Stress management techniques together with exercise could further reduce blood glucose levels while improving general health. The press therapies would be designed to work synergistically with acute pulse therapies to further target glucose and glutamine metabolism. Pulse therapies would involve drug cocktails and procedures that work synergistically with the press therapy to *gradually* degrade and eradicate the tumor cells. The drugs chosen would target simultaneously glycolysis in the cytoplasm and substrate-level phosphorylation in the mitochondria. Hence, diets, drugs, and procedures that restrict availability of glucose and glutamine could deprive GBM cells of the fuels necessary for growth while avoiding damage to normal cells of the brain and body.

Conclusions {#sec16-1759091418818261}
===========

We review evidence that describes abnormalities in the number, structure, and function of mitochondria in GBM. These abnormalities, together with expression of the PKM2 isoform, would compromise effective energy production through OxPhos and glycolysis, respectively. We also describe a framework for how provision of high-energy phosphates through mSLP in GBM could compensate for the loss of energy production through both glycolysis and OxPhos. A reliance on mSLP using glucose through cytoplasmic glycolysis and glutamine through glutaminolysis will cause the cancer cells to enter their default state of unbridled proliferation, that is, the state of existence for all cells prior the emergence of atmospheric oxygen ([@bibr235-1759091418818261]; [@bibr226-1759091418818261]; [@bibr211-1759091418818261]). The unbridled proliferation of GBM cells should not be viewed as a growth advantage but rather as a pathological phenotype arising from defective OxPhos with compensatory substrate-level phosphorylation occurring in the cytoplasm and in the mitochondria ([@bibr201-1759091418818261]; [@bibr212-1759091418818261]). The simultaneous restriction of glucose and glutamine, while under therapeutic ketosis, will deprive GBM cells of substrates for growth and energy production. This information should have value in the clinic.
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